There is no arguing that the last year has been a rocky one for biotech companies, but trends suggest that the sector is ready for an upswing. The revenue model works, innovation continues to bear fruit, and the need is ever-present. The harsh winter will result in a hearty harvest.

Leave a Reply

Your email address will not be published. Required fields are marked *